Protease-activated receptor-2 regulates cyclooxygenase-2 expression in human bile duct cancer via the pathways of mitogen-activated protein kinases and nuclear factor kappa B

Journal of Hepato-Biliary-Pancreatic Sciences

Volumn 18, Issue 2, 2011, Pages 147-153

  Eguchi, Hidetoshi ^a   Iwaki, Kentaro ^a   Shibata, Kohei ^a   Ogawa, Tadashi ^a   Ohta, Masayuki ^a   Kitano, Seigo ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Bile duct cancer; Cyclooxygenase 2; Mitogen activated protein kinase; Nuclear factor kappa B; Protease activated receptor 2

Indexed keywords

CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PROTEINASE ACTIVATED RECEPTOR 2;

ARTICLE; BILE DUCT CANCER; CANCER CELL; CONTROLLED STUDY; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; CELL LINE, TUMOR; CYCLOOXYGENASE 2; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MITOGEN-ACTIVATED PROTEIN KINASES; NF-KAPPA B; POLYMERASE CHAIN REACTION; RECEPTOR, PAR-2; RNA, MESSENGER; SIGNAL TRANSDUCTION;

EID: 79959827808     PISSN: 18686974     EISSN: 18686982     Source Type: Journal    
DOI: 10.1007/s00534-010-0318-9     Document Type: Article

References (42)

1. Ishak KG, Anthony PP, Sobin LH. Histological typing of tumours of the liver. WHO international histological classification of tumours. Berlin: Springer; 1994.
2. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115-25. (Pubitemid 38738341)
3. Babbitt DP. Congenital choledochal cyst: new etiological concept based on anomalous relationships of the common bile duct and pancreatic bulb. Ann Radiol (Paris). 1969;12:231-40.
4. Tsuchiya R, Harada N, Ito T, Furukawa M, Yoshihiro I. Malignant tumors in choledochal cyst. Ann Surg. 1977;186:22-8.
5. Kinoshita H, Nagata E, Hirohashi K, Sakai K, Kobayashi Y. Carcinoma of the gallbladder with an anomalous connection between the choledochus and the pancreatic duct. Cancer. 1984;54:762-9.
6. Mori K, Nagakawa T, Ohta T, Nakano T, Kayahara M, Kanno M, et al. Association between gallbladder cancer and anomalous union of the pancreaticobiliary duct system. Hepatogastroenterology. 1993;40:56-60.
7. Sandoh N, Shirai Y, Hatakeyama K. Incidence of anomalous union of the pancreaticobiliary ductal system in biliary cancer. Hepatogastroenterology. 1997;44:1580-3.
8. Chao TC, Jan YY, Chen MF. Primary carcinoma of the gallbladder associated with anomalous pancreaticobiliary ductal junction. J Clin Gastroenterol. 1995;21:306-8.
9. Yamauchi S, Koga A, Matsumoto S, Tanaka M, Nakayama F. Anomalous junction of pancreaticobiliary duct without congenital choledochal cyst: a possible risk factor for gallbladder carcinoma. Am J Gastroenterol. 1987;82:20-4. (Pubitemid 17231678)
10. Nagata E, Sakai K, Kinoshita H, Kobayashi Y. The relation between carcinoma of the gallbladder and an anomalous connection between the choledochus and the pancreatic duct. Ann Surg. 1985;202:182-90. (Pubitemid 15041718)
11. Hollenberg MD. Protease-mediated signaling: new paradigms for cell regulation and drug development. Trends Pharmacol Sci. 1996;17:3-6. (Pubitemid 26027735)
12. Steinhoff M, Buddenkotte J, Shpacovitch V, Rattenholl A, Moormann C, Vergnolle N, et al. Proteinase-activated receptors: transducers of proteinase-mediated signaling in inflammation and immune response. Endocr Rev. 2005;26:1-43. (Pubitemid 40209385)
13. Ramachandran R, Hollenberg MD. Proteinases and signaling: pathophysiological and therapeutic implications via PARs and more. Br J Pharmacol. 2008;153(Suppl 1):S263-82.
14. Brass LF, Molino M. Protease-activated G protein-coupled receptors on human platelets and endothelial cells. Thromb Haemost. 1997;78:234-41. (Pubitemid 27289247)
15. Bohm SK, Kong W, Bromme D, Smeekens SP, Anderson DC, Connolly A, et al. Molecular cloning, expression and potential functions of the human proteinase-activated receptor-2. Biochem J. 1996;314(Part 3):1009-16. (Pubitemid 26097768)
16. Nystedt S, Emilsson K, Larsson AK, Strombeck B, Sundelin J. Molecular cloning and functional expression of the gene encoding the human proteinase-activated receptor 2. Eur J Biochem. 1995;232:84-9.
17. D'Andrea MR, Derian CK, Leturcq D, Baker SM, Brunmark A, Ling P, et al. Characterization of protease-activated receptor-2 immunoreactivity in normal human tissues. J Histochem Cytochem. 1998;46:157-64. (Pubitemid 28087846)
18. Yoshii M, Jikuhara A, Mori S, Iwagaki H, Takahashi HK, Nishibori M, Tanaka N. Mast cell tryptase stimulates DLD-1 carcinoma through prostaglandin- and MAP kinase-dependent manners. J Pharmacol Sci. 2005;98:450-8. (Pubitemid 41297020)
19. Fujimoto D, Hirono Y, Goi T, Katayama K, Hirose K, Yamaguchi A. Expression of protease activated receptor-2 (PAR-2) in gastric cancer. J Surg Oncol. 2006;93:139-44. (Pubitemid 43235260)
20. Ikeda O, Egami H, Ishiko T, Ishikawa S, Kamohara H, Hidaka H, et al. Expression of proteinase-activated receptor-2 in human pancreatic cancer: a possible relation to cancer invasion and induction of fibrosis. Int J Oncol. 2003;22:295-300.
21. Shibata K, Yada K, Matsumoto T, Sasaki A, Ohta M, Kitano S. Protease-activating-receptor-2 is frequently expressed in papillary adenocarcinoma of the gallbladder. Oncol Rep. 2004;12: 1013-6.
22. Darmoul D, Marie JC, Devaud H, Gratio V, Laburthe M. Initiation of human colon cancer cell proliferation by trypsin acting at protease-activated receptor-2. Br J Cancer. 2001;85:772-9. (Pubitemid 32929479)
23. Ohta T, Shimizu K, Yi S, Takamura H, Amaya K, Kitagawa H, et al. Protease-activated receptor-2 expression and the role of trypsin in cell proliferation in human pancreatic cancers. Int J Oncol. 2003;23:61-6.
24. Yada K, Shibata K, Matsumoto T, Ohta M, Yokoyama S, Kitano S. Protease-activated receptor-2 regulates cell proliferation and enhances cyclooxygenase-2 mRNA expression in human pancreatic cancer cells. J Surg Oncol. 2005;89:79-85. (Pubitemid 40189814)
25. Iwaki K, Shibata K, Ohta M, Endo Y, Uchida H, Tominaga M, et al. A small interfering RNA targeting proteinase-activated receptor-2 is effective in suppression of tumor growth in a Panc1 xenograft model. Int J Cancer. 2008;122:658-63. (Pubitemid 350308962)
26. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J Natl Cancer Inst. 1998;90:1609-20. (Pubitemid 28523435)
27. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995;333:609-14.
28. Marnett LJ, DuBois RN. COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol. 2002;42:55-80. (Pubitemid 34160519)
29. Sirica AE. Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology. 2005;41:5-15. (Pubitemid 40066375)
30. Wu T. Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma. Biochim Biophys Acta. 2005;1755:135-50. (Pubitemid 40982563)
31. Kiguchi K, Carbajal S, Chan K, Beltran L, Ruffino L, Shen J, et al. Constitutive expression of ErbB-2 in gallbladder epithelium results in development of adenocarcinoma. Cancer Res. 2001;61: 6971-6. (Pubitemid 32946479)
32. Endo K, Yoon BI, Pairojkul C, Demetris AJ, Sirica AE. ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology. 2002;36: 439-50. (Pubitemid 34810365)
33. Han C, Leng J, Demetris AJ, Wu T. Cyclooxygenase-2 promotes human cholangiocarcinoma growth: evidence for cyclooxygenase- 2-independent mechanism in celecoxib-mediated induction of p21waf1/cip1 and p27kip1 and cell cycle arrest. Cancer Res. 2004; 64:1369-76. (Pubitemid 38235605)
34. Wu T, Leng J, Han C, Demetris AJ. The cyclooxygenase-2 inhibitor celecoxib blocks phosphorylation of Akt and induces apoptosis in human cholangiocarcinoma cells. Mol Cancer Ther. 2004;3:299-307. (Pubitemid 39193705)
35. Syeda F, Grosjean J, Houliston RA, Keogh RJ, Carter TD, Paleolog E, et al. Cyclooxygenase-2 induction and prostacyclin release by protease-activated receptors in endothelial cells require cooperation between mitogen-activated protein kinase and NF-kappaB pathways. J Biol Chem. 2006;281:11792-804. (Pubitemid 43855439)
36. Kawao N, Nagataki M, Nagasawa K, Kubo S, Cushing K, Wada T, Sekiguchi F, Ichida S, Hollenberg MD, MacNaughton WK, Nishikawa H, Kawabata A. Signal transduction for proteinase-activated receptor-2-triggered prostaglandin E2 formation in human lung epithelial cells. J Pharmacol Exp Ther. 2005;315: 576-89. (Pubitemid 41500722)
37. Nzeako UC, Guicciardi ME, Yoon JH, Bronk SF, Gores GJ. COX-2 inhibits Fas-mediated apoptosis in cholangiocarcinoma cells. Hepatology. 2002;35:552-9. (Pubitemid 34183958)
38. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83:493-501.
39. Darmoul D, Gratio V, Devaud H, Laburthe M. Protease-activated receptor 2 in colon cancer: trypsin-induced MAPK phosphorylation and cell proliferation are mediated by epidermal growth factor receptor transactivation. J Biol Chem. 2004;279:20927-34. (Pubitemid 38656491)
40. Wang H, Wen S, Bunnett NW, Leduc R, Hollenberg MD, MacNaughton WK. Proteinase-activated receptor-2 induces cyclooxygenase-2 expression through beta-catenin and cyclic AMP-response element-binding protein. J Biol Chem. 2008;283: 809-15.
41. Jikuhara A, Yoshii M, Iwagaki H, Mori S, Nishibori M, Tanaka N. MAP kinase-mediated proliferation of DLD-1 carcinoma by the stimulation of protease-activated receptor 2. Life Sci. 2003; 73:2817-29. (Pubitemid 37153356)
42. Yoon JH, Higuchi H, Werneburg NW, Kaufmann SH, Gores GJ. Bile acids induce cyclooxygenase-2 expression via the epidermal growth factor receptor in a human cholangiocarcinoma cell line. Gastroenterology. 2002;122:985-93. (Pubitemid 34267282)